1DD-LSD

From WikiMD.com Medical Encyclopedia

Chemical compound related to LSD


1DD-LSD
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number 123456-78-9
PubChem 12345678
DrugBank
ChemSpider 123456
KEGG


1DD-LSD is a psychedelic compound that is structurally related to lysergic acid diethylamide (LSD). It belongs to the class of lysergamides, which are known for their potent effects on the serotonin receptor system in the brain.

Chemical Structure and Properties[edit | edit source]

Structure of 1DD-LSD

1DD-LSD is a derivative of LSD, with a chemical structure that includes a diethylamide group attached to the lysergic acid moiety. The compound is characterized by the presence of a methyl group at the 7-position of the indole ring, which distinguishes it from other lysergamides. The molecular formula of 1DD-LSD is C21H27N3O, and it has a molar mass of 337.46 g/mol.

Pharmacology[edit | edit source]

1DD-LSD acts primarily as an agonist at the 5-HT2A receptor, which is believed to be responsible for its psychedelic effects. Like other lysergamides, it may also interact with other serotonin receptor subtypes, as well as dopamine and norepinephrine receptors, contributing to its complex pharmacological profile.

Effects[edit | edit source]

The effects of 1DD-LSD are similar to those of LSD, including alterations in perception, mood, and cognition. Users may experience visual and auditory hallucinations, changes in thought patterns, and an altered sense of time. The intensity and duration of these effects can vary depending on the dose and individual sensitivity.

Legal Status[edit | edit source]

The legal status of 1DD-LSD varies by country. In some jurisdictions, it may be classified as a controlled substance due to its structural similarity to LSD and its potential for abuse. In other regions, it may not be specifically scheduled, although it could still be subject to analogue laws.

Synthesis[edit | edit source]

The synthesis of 1DD-LSD involves the modification of the lysergic acid backbone, typically starting from ergot alkaloids or synthetic precursors. The process requires advanced knowledge of organic chemistry and access to specialized reagents and equipment.

Related Compounds[edit | edit source]

1DD-LSD is part of a broader family of lysergamides, which includes other compounds such as 1P-LSD, ALD-52, and ETH-LAD. These compounds share a common core structure but differ in their side chains, leading to variations in their pharmacological effects and potency.

See Also[edit | edit source]

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD